This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Protionamide is an antitubercular thioamide-derivative used in the treatment of multi-drug resistant (MDR) tuberculosis and leprosy.

Generic Name
Protionamide
DrugBank Accession Number
DB12667
Background

Prothionamide has been used in trials studying the treatment of MDR-TB and HIV Infections.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 180.27
Monoisotopic: 180.072119568
Chemical Formula
C9H12N2S
Synonyms
  • Prothionamide
  • Protionamida
  • Protionamide
  • Protionamidum
External IDs
  • RP 9778
  • RP-9778
  • TH 1321
  • TH-1321

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Protionamide is combined with Acenocoumarol.
Bacillus calmette-guerin substrain russian BCG-I live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Protionamide.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Protionamide.
DicoumarolThe risk or severity of bleeding can be increased when Protionamide is combined with Dicoumarol.
EstetrolThe therapeutic efficacy of Estetrol can be decreased when used in combination with Protionamide.
FluindioneThe risk or severity of bleeding can be increased when Protionamide is combined with Fluindione.
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Protionamide.
MagnesiumThe serum concentration of Magnesium can be decreased when it is combined with Protionamide.
PhenindioneThe risk or severity of bleeding can be increased when Protionamide is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Protionamide is combined with Phenprocoumon.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Ektebin / Peteha / Trevintix

Categories

ATC Codes
J04AD01 — Protionamide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyridines and derivatives. These are compounds containing a pyridine ring, which is a six-member aromatic heterocycle which consists of one nitrogen atom and five carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Not Available
Direct Parent
Pyridines and derivatives
Alternative Parents
Thioamides / Heteroaromatic compounds / Thiocarboxylic acid amides / Azacyclic compounds / Thiocarbonyl compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
Substituents
Aromatic heteromonocyclic compound / Azacycle / Heteroaromatic compound / Hydrocarbon derivative / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound / Organosulfur compound / Pyridine / Thioamide
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
76YOO33643
CAS number
14222-60-7
InChI Key
VRDIULHPQTYCLN-UHFFFAOYSA-N
InChI
InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12)
IUPAC Name
2-propylpyridine-4-carbothioamide
SMILES
CCCC1=CC(=CC=N1)C(N)=S

References

General References
  1. TITCK Product Information: Promid (protionamide) coated tablets for oral use [Link]
KEGG Drug
D01195
PubChem Compound
666418
PubChem Substance
347828871
ChemSpider
579891
BindingDB
50499814
RxNav
8871
ChEBI
32066
ChEMBL
CHEMBL1378024
ZINC
ZINC000003874803
Wikipedia
Prothionamide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentTuberculosis, Multidrug Resistant1
3Active Not RecruitingTreatmentTuberculosis, Multidrug Resistant1
1CompletedTreatmentHealthy Subjects (HS)1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coated
Tablet, coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.296 mg/mLALOGPS
logP2.25ALOGPS
logP1.77ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)11.89ChemAxon
pKa (Strongest Basic)4.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.91 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.79 m3·mol-1ChemAxon
Polarizability20.09 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-1900000000-4e2e325a8024a29d1946
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-3900000000-ebf07b82c23f40b432ab

Drug created at October 20, 2016 23:32 / Updated at June 08, 2021 11:32